Patient-derived cell-based pharmacogenomic assessment to unveil underlying resistance mechanisms and novel therapeutics for advanced lung cancer

The Reactome database helped Yu et al. in the January 2023 issue of the Journal of Experimental & Clinical Cancer Research identify candidate drugs for treatment of four subtypes of lung cancer that were categorized by pharmaco-genomic analysis of patient-derived cells and correlated with drug sensitivity of the patient-derived cells and with Reactome pathways identified by gene set variation analysis.